Tazemetostat
Back to searchMolecule Structure
Scientific Name
Tazemetostat
Description of the Drug
Tazemetostat is a methyltransferase inhibitor indicated to treat patients 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB12887
http://www.drugbank.ca/drugs/DB12887
Brand Name(s)
Not Available
Company Owner(s)
Epizyme Inc
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
Histone-lysine N-methyltransferase EZH2 | SINGLE PROTEIN | INHIBITOR | CHEMBL2189110 |
Clinical Trial(s)
Unichem Links
SureChEMBL | SCHEMBL19325409 | SCHEMBL13276848 | SCHEMBL22210809 |
Human Metabolome Database | HMDB0304867 | ||
DrugBank | DB12887 | ||
PubChem: Thomson Pharma | 152189092 | 163426746 | |
PubChem | 66558664 | ||
Nikkaji | J3.394.917K | ||
BindingDB | 172038 | ||
DrugCentral | 5380 | ||
ChemicalBook | CB82655404 | ||
Guide to Pharmacology | 7011 | ||
rxnorm | TAZEMETOSTAT | ||
ZINC | ZINC000100285161 |